Patient Guide: Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 19 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT06082102
Status: 🟢 Enrolling Now
Condition: Relapsed/Refractory Marginal Zone Lymphoma
Phase: PHASE3

Where You Can Participate

This study is available at 19 locations across the country.

Top locations include:
  • • Bengbu, Auhui
  • • Beijing, Beijing
  • • Beijing, Beijing
  • • And 16 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma - Join Clinical Trial NCTNCT06082102

How to Join This Clinical Trial - NCTNCT06082102

Learn how to participate in this PHASE3 trial studying an investigational therapy for Relapsed/Refractory Marginal Zone Lymphoma. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Relapsed/Refractory Marginal Zone Lymphoma. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Relapsed/Refractory Marginal Zone Lymphoma
Treatment Being Tested
Investigational treatment
Study Phase
PHASE3 - Large-scale efficacy study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT06082102 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 19 locations. Find a study site near you:

Clinical Research Site

Bengbu, Auhui 233000 - China

Status: RECRUITING

Clinical Research Site

Beijing, Beijing 100070 - China

Status: RECRUITING

Clinical Research Site

Beijing, Beijing 100730 - China

Status: RECRUITING

Clinical Research Site

Guangzhou, Guangdong 510055 - China

Status: RECRUITING

Clinical Research Site

Guangzhou, Guangdong 510120 - China

Status: RECRUITING

Clinical Research Site

Zhengzhou, Henan 450003 - China

Status: RECRUITING

Clinical Research Site

Zhengzhou, Henan 450003 - China

Status: RECRUITING

Clinical Research Site

Wuhan, Hubei 430000 - China

Status: RECRUITING

Clinical Research Site

Changsha, Hunan 410000 - China

Status: NOT_YET_RECRUITING

Clinical Research Site

Nanchang, Jiangxi 330006 - China

Status: RECRUITING

And 9 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE3 clinical trial for Relapsed/Refractory Marginal Zone Lymphoma:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships